Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$102.49 USD

102.49
9,365,005

-2.34 (-2.23%)

Updated Oct 31, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Factors That Make Elevance Health (ELV) a Lucrative Bet Now

by Zacks Equity Research

Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.

Should Value Investors Buy Innoviva (INVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Merck & Co., Inc. (MRK) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

by Zacks Equity Research

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication

by Kinjel Shah

Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.

Novartis (NVS) Set to Advance Malaria Drug Into Phase III

by Zacks Equity Research

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

by Zacks Equity Research

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision expected by Dec 14.

AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

by Zacks Equity Research

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

GSK to Withdraw Blenrep From U.S. Market on FDA Request

by Zacks Equity Research

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co

by Zacks Equity Research

Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.

Encompass Health (EHC) Proposes 50-Bed Hospital in Florida

by Zacks Equity Research

Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.

Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck

by Zacks Equity Research

Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.

Nalak Das headshot

Buy These 5 Corporate Giants Flying High in Disappointing 2022

by Nalak Das

We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.

AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.

Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug

by Zacks Equity Research

Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.

Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Merck (MRK) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.

Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval

by Zacks Equity Research

Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.

Kinjel Shah headshot

Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo

by Kinjel Shah

Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.

Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.

Novartis (NVS) Reportedly Looking to Sell Its Business Units

by Zacks Equity Research

Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.

Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?

by Zacks Equity Research

Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use

by Zacks Equity Research

The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.